首页> 外文期刊>The journal of sexual medicine >Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study.
【24h】

Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study.

机译:A型肉毒杆菌毒素-引发前庭性运动障碍的新疗法吗?一项随机,安慰剂对照,双盲研究的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Vestibulodynia is an increasingly recognized problem among women and is often difficult to treat. AIM: This randomized, double blinded, placebo-controlled study aimed to evaluate the efficacy of Botox in the treatment of vestibulodynia. METHODS: Sixty-four women were randomized to receive Botox (N = 32) or saline placebo (N = 32). Botulinum toxin A (20 I.E.) diluted in 0.5 mL saline or 0.5 mL saline was injected in the musculus bulbospongiosus at baseline. MAIN OUTCOME MEASURES: Pain was measured monthly on a visual analog scale (VAS) Likert scale. Sexual function was measured using the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale at baseline and at 3 and 6 months follow up. Quality of life was measured using the 36-item short-form (SF-36). RESULTS: Sixty women (94%) completed the 6 months follow up. Both Botox and placebo produced significantly pain reduction (P < 0.001). There was no significant difference in the median VAS score between the groups at 6 months follow up (P = 0.984). An improvement on the FSFI full score from baseline until 6 months was not significantly different between the groups (P = 0.635). In the placebo group a statistical significant larger reduction in sexual distress was observed from baseline until 6 months follow up compared to the Botox group (P = 0.044). No statistical significant differences were observed between the B- and P-groups in regard to the SF-36 scores. CONCLUSION: Injection of 20 I.E. Botox in the vestibule of women diagnosed with vestibulodynia does not reduce pain, improve sexual functioning, or impact the quality of life compared to placebo and evaluated at 3 and 6 moths follow up. Both the Botox group and the placebo groups experienced a reduction in pain on the VAS Likert scale at 6 months follow up. Women with vestibulodynia have difficulty with sexual function and present with sexual distress, which has to be addressed in conjunction with pain to eliminate the disorder.
机译:引言:女性上皮痛觉障碍是一个日益被人们认识的问题,通常难以治疗。目的:这项随机,双盲,安慰剂对照的研究旨在评估肉毒杆菌毒素治疗前庭痛觉的功效。方法:64名妇女被随机分配接受肉毒杆菌毒素(N = 32)或生理盐水安慰剂(N = 32)。在基线时,将用0.5 mL盐水或0.5 mL盐水稀释的肉毒杆菌毒素A(20 I.E.)注射到球囊肌肉中。主要观察指标:每月以视觉模拟量表(VAS)李克特量表测量疼痛。在基线时以及随访的3个月和6个月时,使用女性性功能指数(FSFI)和女性性窘迫量表测量性功能。使用36项简短内容(SF-36)测量生活质量。结果:60名妇女(94%)完成了6个月的随访。肉毒杆菌毒素和安慰剂均可显着减轻疼痛(P <0.001)。随访6个月时,两组间的VAS评分中位数无显着差异(P = 0.984)。从基线到6个月,FSFI全评分的改善在两组之间无显着差异(P = 0.635)。与肉毒杆菌素治疗组相比,安慰剂组从基线到随访6个月观察到性困扰的统计学显着减少(P = 0.044)。 B组和P组之间在SF-36评分方面未观察到统计学显着差异。结论:注射20 I.E.与安慰剂相比,经3个月和6个月的随访评估,被诊断为前庭神经痛的妇女前庭的肉毒杆菌毒素不会减轻疼痛,改善性功能或影响生活质量。肉毒杆菌素组和安慰剂组在6个月的随访中均经历了VAS Likert量表的疼痛减轻。前庭神经痛的妇女在性功能上有困难,并且表现出性困扰,这必须与疼痛相结合才能消除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号